European life sciences venture capital firm Medicxi has closed Medicxi V, a €500 million fund dedicated to backing biotech companies with clear product visions and a focus on improving patient care.
The fund exceeded its original fundraising target, attracting strong commitments from existing LPs as well as several new institutional investors.
Asset-Centric Strategy Continues
Medicxi V will extend the firm’s asset-focused investment model, supporting:
- Single-asset biotech startups
- Focused drug development programs
- Existing Medicxi portfolio companies
- Select external companies aligned with the same approach
The firm aims to move promising drug programs more efficiently toward clinical milestones and commercial readiness.
Leadership Commentary
Francesco De Rubertis, Co-founder & Partner at Medicxi:
“Our success comes from its deep relationships with global pharmaceutical companies and a world-class team of drug hunters and clinicians. This new €500M fund strengthens our ability to provide the capital and expertise needed to deliver transformative therapies for patients.”
Medicxi also announced the promotion of Shyam Masrani to Partner. Masrani oversees key relationships with Merus and ProfoundBio and sits on the boards of Acera Therapeutics, T-CypherBio, and Petalion Therapeutics.
Fund V will be managed by De Rubertis, Giovanni Mariggi, Nick Williams, and Masrani.
Giovanni Mariggi, Co-founder & Partner at Medicxi:
“Our differentiated, capital-efficient investment strategy continues to scale. With six funds raised in ten years—totalling over €2 billion—we’re grateful for the trust of our LPs and remain committed to investing in cutting-edge science to accelerate life-changing medicines.”
Advertisement
A Track Record of Clinical and Commercial Success
Founded in 2016, the company builds on more than two decades of experience in biotech company creation and drug development. The firm invests from early research through late clinical stages with products designed to address specific unmet medical needs.
Since its previous fundraise, the VC firm has:
- Created 16 new companies
- Achieved 20+ clinical readouts across its portfolio
- Generated over $1 billion in exits and public listings
Notable successes include Vaxcyte, Merus, and Abivax, alongside acquisitions such as:
- ViceBio → acquired by Sanofi
- Versanis Bio → acquired by Eli Lilly
- ProfoundBio → acquired by Genmab
About Medicxi
Medicxi is a leading European life sciences venture capital firm with offices in London, St. Helier, and Geneva. Focused on biotech innovation, the VC company invests across the entire drug development lifecycle—from early-stage programs to advanced clinical assets—supporting companies developing therapies that address critical patient needs worldwide.
